mass. mover

Sales of AMAG injection soar 33 percent

AMAG reported record sales of its Feraheme injection.


AMAG reported record sales of its Feraheme injection.


AMAG Pharmaceuticals reported a third-quarter net loss of $145,000, or 1 cent per share, compared with a net loss of $4 million, or 19 cents, a year earlier. The Waltham-based pharmaceutical company also said US sales of its Feraheme injection, which treats iron deficiency anemia in adults, were up 33 percent. During the quarter, AMAG also began promoting MuGard Mucoadhesive Oral Wound Rinse, which it licensed from Access Pharmaceuticals Inc. earlier this year.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of